Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthLTS:0QYW 65 OCF Margin % is 23.49% as of Jun. 2026, which is 40% above its 10-year median of 16.75. GuruFocus rates LTS:0QYW with a GF Score™ of 65/100 and a GF Value™ of CHF157.98. The stock has 3 warning signs investors should review. Among 963 Drug Manufacturers companies, Bausch Health ranks better than 70.51% on this metric.
The historical data trend for Bausch Health's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bausch Health's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (LTS:0QYW) has a OCF Margin % of 23.49% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bausch Health and its competitors. This is 40% above median its historical median of 16.75. According to the industry distribution chart, Bausch Health ranks #284 out of 963 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Bausch Health's OCF Margin % too high?
Bausch Health's current OCF Margin % of 23.49% is 40% above median its 10-year median of 16.75. The Drug Manufacturers industry median OCF Margin % is 9.94. Bausch Health's value of 23.49% is 136.3% above this industry median. Based on the distribution chart, Bausch Health ranks #284 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #284 out of 963 companies for OCF Margin %. This puts Bausch Health in the upper half of its industry. The industry median OCF Margin % is 9.94. Bausch Health's value of 23.49% is 136.3% above this benchmark. While the company's 10-year median is 16.75 vs. the industry median of 9.94, Bausch Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current OCF Margin % of 23.49% is 136.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current OCF Margin % is 23.49%, which is 40% above median its own 10-year median of 16.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current OCF Margin % of 23.49%. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current OCF Margin % is 23.49%, which is 40% above median its 10-year median of 16.75 and 136.3% above the Drug Manufacturers industry median of 9.94. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current OCF Margin % is 23.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (LTS:0QYW) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.
Key valuation signals for LTS:0QYW:
OCF Margin %: 23.49% (40% above median its 10-year median of 16.75)
GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
Industry Position: 136.3% above the Drug Manufacturers median (#284 of 963)
No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score
Get the complete analysis for LTS:0QYW
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QYW has been successfully added to your 
